Laboratory for Bone Metabolism, Key Lab for Space Biosciences and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi, 710072, China.
Department of Pathology, The School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Int J Biol Sci. 2020 Mar 12;16(9):1629-1639. doi: 10.7150/ijbs.41867. eCollection 2020.
G-protein-coupled receptors (GPCRs) are pivotal drug targets for many diseases. Coagulation Factor II Thrombin Receptor (F2R) is an important member of GPCR family that is highly expressed in osteoclasts. However, the role of F2r in osteoclasts is still unclear. Here, to examine the functions of F2r on osteoclast formation, differentiation, activation, survival, and acidification, we employed loss-of-function and gain-of-function approaches to study F2r using F2r-targeted short hairpin RNA (sh-F2r) lentivirus and overexpression plasmid pLX304-F2r lentivirus respectively, in mouse bone marrow cells (MBMs) induced osteoclasts. We used three shRNAs targeting F2r which had the ability to efficiently and consistently knock down the expression of F2r at different levels. Notably, F2r knockdown trigged a significant increase in osteoclast activity, number, and size, as well as promoted bone resorption and F-actin ring formation with increased osteoclast marker gene expression. Moreover, F2r overexpression blocked osteoclast formation, maturation, and acidification, indicating that F2r negatively regulates osteoclast formation and function. Furthermore, we investigated the mechanism(s) underlying the role of F2r in osteoclasts. We detected RANKL-induced signaling pathways related protein changes F2r knockdown cells and found significantly increased pAkt levels in sh-F2r infected cells, as well as significantly enhanced phosphorylation of p65 and IKBα in early stages of RANKL stimulation. These data demonstrated that F2r responds to RANKL stimulation to attenuate osteoclastogenesis through inhibiting the both F2r-Akt and F2r-NFκB signaling pathways, which lead a reduction in the expression of osteoclast genes. Our study suggests that targeting F2r may be a novel therapeutic approach for bone diseases, such as osteoporosis.
G 蛋白偶联受体(GPCRs)是许多疾病的重要药物靶点。凝血因子 II 血栓受体(F2R)是 GPCR 家族的重要成员,在破骨细胞中高度表达。然而,F2r 在破骨细胞中的作用尚不清楚。在这里,为了研究 F2r 对破骨细胞形成、分化、激活、存活和酸化的作用,我们采用了 F2r 靶向短发夹 RNA(sh-F2r)慢病毒和过表达质粒 pLX304-F2r 慢病毒的失活和激活功能方法,分别在小鼠骨髓细胞(MBMs)诱导的破骨细胞中进行研究。我们使用了三种靶向 F2r 的 shRNA,它们能够在不同水平上有效地和一致地敲低 F2r 的表达。值得注意的是,F2r 的敲低导致破骨细胞活性、数量和大小的显著增加,并促进了骨吸收和 F-actin 环的形成,同时增加了破骨细胞标记基因的表达。此外,F2r 的过表达阻断了破骨细胞的形成、成熟和酸化,表明 F2r 负调控破骨细胞的形成和功能。此外,我们研究了 F2r 在破骨细胞中作用的机制。我们检测了 F2r 敲低细胞中 RANKL 诱导的信号通路相关蛋白的变化,发现 sh-F2r 感染细胞中的 pAkt 水平显著升高,并且在 RANKL 刺激的早期阶段 p65 和 IKBα 的磷酸化明显增强。这些数据表明,F2r 对 RANKL 刺激的反应通过抑制 F2r-Akt 和 F2r-NFκB 信号通路来减弱破骨细胞的形成,从而导致破骨细胞基因的表达减少。我们的研究表明,靶向 F2r 可能是骨质疏松症等骨骼疾病的一种新的治疗方法。